EA201491695A1 - TREATMENT OF CANCER TOR-KINASE INHIBITORS - Google Patents

TREATMENT OF CANCER TOR-KINASE INHIBITORS

Info

Publication number
EA201491695A1
EA201491695A1 EA201491695A EA201491695A EA201491695A1 EA 201491695 A1 EA201491695 A1 EA 201491695A1 EA 201491695 A EA201491695 A EA 201491695A EA 201491695 A EA201491695 A EA 201491695A EA 201491695 A1 EA201491695 A1 EA 201491695A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
breast cancer
cancer
tor
kinase inhibitors
Prior art date
Application number
EA201491695A
Other languages
Russian (ru)
Other versions
EA039396B1 (en
Inventor
Шуйчань Сюй
Кристен Мей Хедж
Хитер Рэймон
Рама К. Нарла
Original Assignee
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority claimed from PCT/US2013/031185 external-priority patent/WO2013138553A1/en
Publication of EA201491695A1 publication Critical patent/EA201491695A1/en
Publication of EA039396B1 publication Critical patent/EA039396B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Представлены способы лечения и предотвращения рака молочной железы с тройным негативным фенотипом или гормон-рецепторного положительного рака молочной железы, включающие введение эффективного количества ингибитора TOR-киназы пациенту, имеющему рак молочной железы с тройным негативным фенотипом или гормон-рецепторный положительный рак молочной железы.Methods for the treatment and prevention of triple negative phenotype breast cancer or hormone receptor positive breast cancer are provided, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative phenotype breast cancer or positive hormone receptor breast cancer.

EA201491695A 2012-10-18 2013-03-14 Treatment of triple negative breast cancer with tor kinase inhibitors EA039396B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715331P 2012-10-18 2012-10-18
PCT/US2013/031185 WO2013138553A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491695A1 true EA201491695A1 (en) 2015-02-27
EA039396B1 EA039396B1 (en) 2022-01-24

Family

ID=80685582

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491695A EA039396B1 (en) 2012-10-18 2013-03-14 Treatment of triple negative breast cancer with tor kinase inhibitors

Country Status (1)

Country Link
EA (1) EA039396B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (en) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Heteroaryl compounds, their compositions and their use as protein kinase inhibitors
BRPI0717773A2 (en) * 2006-10-19 2013-11-05 Signal Pharm Llc COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATING OR PREVENTING CANCER, AN INFLAMMATORY CONDITION, IMMUNOLOGICAL CONDITION OR METHODOLOGICAL CONDITION, AND FOR INHIBITING A KINASE IN A CELL EXPRESSING DITA KINASE
US20090258096A1 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
EA039396B1 (en) 2022-01-24

Similar Documents

Publication Publication Date Title
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2015014596A (en) Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer.
IN2015DN01156A (en)
MX368286B (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer.
PH12016502355B1 (en) Pharmaceutical composition
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
EA201490814A1 (en) TREATMENT OF MALIGNANT TUMOR INHIBITORS TOR-KINASE
EA201491699A1 (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
PH12016502353A1 (en) Pharmaceutical composition
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
MX2015014599A (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer.
PH12016502352A1 (en) Pharmaceutical composition
SA515370011B1 (en) Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
EA201491695A1 (en) TREATMENT OF CANCER TOR-KINASE INHIBITORS